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ABSTRACT: 
Imaging biomarkers for predictive assessment of treatment response in oncology patient 
earlier than standard tumor volumetric metrics would provide new opportunities to individualize 
therapy. Diffusion-weighted MRI (DW-MRI), highly sensitive to microenvironmental alterations 
at the cellular level, has been extensively evaluated as a technique for generating quantitative and 
early imaging biomarkers of therapeutic response and clinical outcome. First demonstrated in a 
rodent tumor model, subsequent studies have shown that DW-MRI can be applied to many 
different solid tumors for detecting changes in cellularity as indirectly measured by an increase 
in the apparent diffusion coefficient (ADC) of water molecules within the lesion. Introducing 
quantitative DW-MRI into the treatment management of cancer patients may aid physicians in 
individualizing therapy thereby minimizing unnecessary systemic toxicity associated with 
ineffective therapies, save valuable time, reduce patient care costs and ultimately improve 
clinical outcome. This review covers the theoretical basis behind the application of DW-MRI to 
monitor therapeutic response in cancer, analytical techniques as well as the results from various 
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INTRODUCTION: 
MONITORING CANCER TREATMENT RESPONSE 
Image-based assessment of cancer treatment response continues to be an active area of 
research with advances in medical imaging instrumentation providing opportunities to 
fundamentally change the clinical management of cancer patients. Magnetic resonance imaging 
(MRI) represents a key modality that has found use in diagnosis, treatment planning, and 
assessment of response and recurrence of solid malignancies. By providing high spatial 
resolution and soft tissue contrast, MRI allows exquisite non-invasive radiographic detection of 
tumor location while also providing for determination of tumor number and dimensions. 
Computed tomography, and soon after MRI, have been used since the 1960s to measure 
gross changes in tumor volume following a therapeutic intervention (1). Although there have 
been advancements in quantitative imaging techniques, such as DW-MRI, DCE-MRI and FDG-
PET, standard practice for patient management and clinical trials continues to employ anatomical 
images to assess tumor response to treatment (2-4). The WHO and the Response Evaluation 
Criteria in Solid Tumors (RECIST) have proposed guidelines primarily based on a single linear 
summation of specific lesions where monitoring morphological changes in tumor volume allows 
for routine measurements for cancer response assessment. Nevertheless, there continues to be 
growing concerns regarding the adequacy of these criteria as some treatments, such as 
molecularly targeted agents, may provide therapeutic benefit without significantly reducing the 
tumor volume (5-7).  These concerns underscore the urgency for development and 
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implementation of reliable response imaging biomarkers or surrogates that can detect response to 
treatment earlier than current methodologies (8,9). 
GENERAL CONCEPTS IN DIFFUSION 
The first diffusion MR sequence was demonstrated in 1965 by Stejskal and Tanner (10), 
and by the 1980s diffusion-weighted MRI of in vivo systems was reported (11-13). Since then 
reviews have been generated on the principle and technical aspects of this MR technique as well 
as consensus recommendations using diffusion imaging as a response metric for treatment 
assessment (14-16). Molecular diffusion is the thermally driven random translational motion of 
molecules in media, which is referred to as Brownian motion. Key factors that exert their 
influence on the mobility of a diffusing molecule include media viscosity, temperature, and its 
molecular mass. Diffusion is not a magnetization-related process like, for example, T1 and T2 
magnetization relaxation that drives conventional MRI contrast. Nevertheless, MRI can be used 
to noninvasively quantify (image) water diffusion values spatially in vivo. This is accomplished 
in part through the use of magnetic gradients that allow for the “encoding” of initial locations of 
constituent water molecules in the tissue. Following a brief interval, the same gradients are used 
to “decode” the molecular locations. For those water molecules in which displacement has 
occurred during the time interval, decoding will be incomplete, resulting in the loss of signal 
through spin dephasing. The dephasing amount increases in proportion to the distance translated 
between encode/decode diffusion gradient pulses. Highly mobile water molecules will have more 
attenuation of the signal relative to water in a more restricted/cellular tissue environments. 
Determination of the degree of signal loss at various diffusion gradient settings provides for the 
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ability to calculate molecular mobility in complex systems, such as tumor tissue. However, 
because tumor tissue is composed of water located in a highly complex microenvironment, the 
concept of a single diffusion coefficient is not valid and as such is reported as an “apparent 
diffusion coefficient” (ADC) (13,14). ADC measurements can be used to assess a myriad of 
properties that impede molecular motions including cell membrane integrity, cell density, 
interactions with macromolecules, as well as processes that enhance mobility via active 
transport, convective motion, and perfusion. 
 The ability of water to sample its surrounding environment is the foundation behind its 
efficacy as a measure of tumor response to cancer. The thermal, i.e. Brownian, motion of free 
water at body temperature (~35°C) is approximately 3 × 10–3 mm2/s. Clinical DW-MRI 
sequences typically have a bipolar gradient interval around 50ms, resulting in the displacement 
of free water molecules of 30 μm. By applying these motion sensitive gradients, water molecules 
can be exploited to sample the microenvironment of biological systems well within the 
resolution of the MRI sequence. Structures within the solid tumor that are sampled by water 
molecules may include the tumor cells membranes, organelles, myelin layers, and 
macromolecules as well as additional cellular and subcellular entities all of which are on the 
order of micrometers. Transient association of water with large, slow-moving macromolecules 
and cell membranes that result in water binding, as well as impediment by membranes and other 
structures, effectively reduce water mobility to an ADC lower than free water diffusion. The 
greater the bulk density of structures within a tumor tissue that impedes water mobility, the lower 
the ADC value for that tumor. As such ADC is considered a noninvasive imaging biomarker of 
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cellularity or cell density. However, if two tissues have different ADC values, the lower ADC 
tissue may not necessarily have the greater number of cells per unit volume. Other factors that 
make up the microenvironment (e.g. cell size, viscosity, vasculature, extracellular matrix and 
permeability) also affect water mobility and ADC. Within a given tissue or cell type, ADC is 
useful as an indicator of the relative cellularity, such as in the evolution of tumor over time 
following therapy. Cellular alterations due to disease or intervention, as well as changes in 
cellular organization or integrity of cellular elements, are available for study by diffusion 
imaging. 
Water diffusion on the order of cellular distances is measurable in spite of the presence of 
other much larger physiologic motions. A single-shot echo-planar imaging (EPI) approach (17) 
is the standard imaging sequence for acquiring diffusion weighted imaging. EPI. By acquiring 
the entire set of echoes for an image within one single scanning period, respiratory bulk tissue 
motion, which would overwhelm the measurement of molecular motion, is essentially 
eliminated. By decreasing acquisition times by a factor of 100, EPI has also allowed DW-MRI to 
be incorporated as a standard MRI sequence in clinical scanners and used in routine clinical 
scanning protocols. However, images generated by EPI are sensitive to artifacts such as 
distortion and signal loss owing to magnetic susceptibility. These limitations aside, EPI is the 
most commonly used clinical sequence combined with diffusion-sensitization gradient pulses to 
perform DW-MRI. 
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ADC AS A MEASURE OF TUMOR CELLULARITY 
It is traditionally viewed that as cellular density increases, the added tortuosity within the 
microenvironment reduces water mobility. Figure 1 illustrates the effect of an effective 
therapeutic agent on the water diffusivity in a solid tumor mass (18). Solid tumors typically have 
a mean ADC value around 1x10-3mm2/s (Figure 1). Following the intervention of a therapeutic 
agent that results in cell kill (i.e. drop in tumor cellularity), the extracellular space increases as 
the intracellular space diminishes (Figure 1). This results in a shift in the tumor water diffusivity 
to higher values in therapeutically responsive regions of the tumor. Several groups have reported 
the inverse relationship between ADC and cellular density (19-22). To aid in interpreting these 
results a biphasic model relating ADC values to cellularity was proposed where two pools of 
water within the tissue exist, a fast diffusion and a slow diffusion pool (23). The slow diffusion 
pool is proposed to consist of a water layer trapped by electrostatic forces of the cellular 
membranes and associated cytoskeleton. The fast diffusion pool is thought to belong to a 
combination of intra- and extracellular compartments that are, however, slower than free water. 
Both the traditional, i.e. monoexponential, and biphasic diffusion models provide for the 
rationale that water diffusion will decrease during cell swelling or cell proliferation and increase 
during treatment-induced loss of cellular viability or density. Regardless of the underlying 
mechanism, the fact remains that tumor diffusion values increase as tumor tissue initially 
progresses from a solid, cellular lesion to an acellular, necrotic tumor during successful cytotoxic 
therapy. This characteristic of tumor water diffusion values provides a key opportunity to use 
This article is protected by copyright. All rights reserved.
this biophysical and quantifiable ADC parameter as a sensitive biomarker for detecting the 
underlying changes of tumor cytoarchitecture associated with treatment (24). 
DIFFUSION IMAGING TO ASSESS TREATMENT RESPONSE 
Twenty years of research in preclinical studies have supported the notion that water 
diffusivity is highly dependent on the tumor microenvironment. This suggests that diffusion MR 
can be used to noninvasively detect cellular changes associated with treatment-induced cell 
killing in animal models (19,20,22,25-30). The key findings in many studies were that changes in 
ADC values preceded changes in tumor volume regression, as well as being treatment-
independent and dose/efficacy-dependent. All of this supports the claim that this imaging 
biomarker may indeed be used as an early surrogate for assessment of treatment outcome. 
Diffusion MRI as a method for therapeutic response assessment in the clinic was first 
demonstrated in glioma patients (21). Tumors treated with radiation with or without 
chemotherapy demonstrated an increase in ADC values from baseline. The magnitude of change 
in ADC values correlated to cellularity in the tumor mass albeit in a pilot study. Through 
advances in rf coil design, parallel imaging and rapid pulse sequencing diffusion MRI as a 
biomarker of treatment response has been demonstrated in breast cancer (31-38) liver cancer (39-
47), prostate cancer (34,48), rectal cancer (49-57), lymphomas (20,58-63), head and neck cancer 
(64,65) and metastases (29,33,37,66-72). Results from clinical studies have shown a significant 
difference in the mean ADC values between patients responding to treatment in comparison to 
patients that were determined to be nonresponsive to treatment.  
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An example of the clinical application of DW-MRI for assessment of early treatment 
response was reported in stage II/III breast cancer patients treated with neoadjuvant 
chemotherapy (NAC) (73). Presented in Figure 2 are representative slices of ADC tumor maps 
from two breast cancer patients who underwent two cycles of neoadjuvant therapy. The first 
patient revealed an increase in tumor diffusion values (Figure 2A), indicating cell killing had 
occurred with no significant reduction in tumor size (Figure 2B). Following the second cycle of 
treatment, a significant decrease in tumor volume was noted. In the second breast cancer patient, 
ADC values remained stable over the treatment period and the patient was subsequently 
classified as non-pCR (Figure 2C, D). This data reveals the tremendous potential that DW-MRI 
has for early monitoring of cancer treatment response. 
While an initial increase in tumor ADC values during treatment is typically associated 
with cell death, a subsequent drop in tumor ADC values may occur indicating tumor regrowth or 
possibly fibrosis. This present understanding is supported by findings in recurrent high-grade 
gliomas and osteosarcomas where lower ADC values are observed in viable tumor and higher 
ADC values in regions of necrosis following treatment (74,75). Thus ADC values in the context 
of determining treatment response should likely be limited to early time intervals post-treatment 
initiation due to the more complex late-stage cellular processes that may complicate 
interpretation.  
Metastatic lesions pose a very distinct problem for treatment management of cancer 
patients with disseminated disease. In many cases, primary tumors that have metastasized will 
seed osseous regions. Although bone scans using Tc99m-SPECT imaging is standard clinical 
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practice for diagnosing metastatic cancer to the bone, RECIST continues to label bony tumors as 
“non-measureable” due to the complex metabolic state of the bone interacting with the tumor. 
DW-MRI with its high soft tissue contrast and resolution has been shown to be highly sensitive 
to tumor response to therapy irrespective of bone turnover. In a preliminary pilot study, Lee and 
colleagues first demonstrated the utility of DW-MRI for therapeutic response assessment in two 
patients with metastatic prostate cancer to the bone (29), which was later validated in a large data 
set by Reischauer and colleagues (76). 
 
WHOLE-BODY DW-MRI 
Although the aforementioned studies (29,76) focused only on treatment response on 
individual tumors, advances in whole body (wb) diffusion-weighted MRI may allow for multiple 
lesions to be monitored simultaneously (77,78). This is illustrated in the work by Horger and 
colleagues were 20 lymphoma patients undergoing systemic therapy are monitored using 
wbDW-MRI (59). Figure 3 demonstrates the sensitivity of wbDW-MRI at detecting variations in 
therapeutic response in a single patient. Multi-focal lesions within the patient were found to have 
increased ADC values, suggesting cell kill occurred following treatment as depicted in these 
inverted gray-scale images (arrows). In contrast, the large tumor in the pelvic node (arrowhead) 
revealed a stable ADC value. Through the use of wbDW-MRI, early response assessment can 
now be obtained over multiple lesions but at a price of reduced spatial resolution. 
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ANOMALIES IN REPORTED DIFFUSION VALUES FOR TUMOR RESPONSE 
Most studies have reported that tumor water ADC values typically increase following 
successful intervention of solid tumors. Although this trend appears to be the norm there have 
been cases where a decrease, rather than an increase, in ADC measurements were reported to 
correlate with positive response (54,79-81). As the tumor mass will respond dynamically 
throughout the course of fractionated therapies consequently, timing of the acquired DW-MRI 
measurement may impact the findings. For example, two studies that investigated the efficacy of 
DW-MRI on treated rectal cancer (54,80) showed a brief, transient increase in ADC in the first 
week post-treatment initiation. Subsequently, a decrease in ADC was observed over the next 
several weeks. Histology confirmed that chemoradiation of rectal carcinoma resulted in 
increased interstitial fibrosis which may have an effect of reducing ADC values in those tumor 
regions (54).  The authors had also drawn attention that regions of obvious necrosis as observed 
by MRI within the tumor mass were not included in the volume of interest prescribed over the 
tumor mass. Omission of the necrotic regions would bias the measurement to lower ADC values.  
Therefore, the reported decreased ADC values that correlated with response appear to be 
primarily related to the timing of the measurement as well as fibrotic formation following tumor 
cell death.   
SPATIAL HETEROGENEITY IN TUMOR RESPONSE 
Spatial heterogeneity in tumor response is a major confounding factor in assigning a 
single indicator to a patient. A given lesion often contains wide gradations of viable cellularity 
and necrosis, and the response of tumor subregions to treatment can be nonuniform and 
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dependent on many factors. Histogram analysis of ADC values throughout the tumor is one 
approach to address heterogeneity (83,84). Although a variety of scalar quantities are derivable 
from tumor ADC histogram analysis, the magnitude of regional changes may be underestimated 
by whole-tumor summary statistics in the presence of heterogeneous response patterns. Figure 4 
from Ref (85) illustrates the affect of response heterogeneity on the tumor histogram. Using 
simulated data, the authors demonstrated that uniform changes in tumor ADC values result in a 
mean ADC that can detect alterations in tumor ADC values (Figure 4B). Although other whole-
tumor metrics may provide more sensitivity, such as the standard deviation for the case when 
regions of the tumor demonstrate increasing and decreasing ADC values from baseline (Figure 
4C), one would have to know a priori the most appropriate measure. A more comprehensive 
evaluation has been performed on the efficacy of histogram-based measures for therapeutic 
response assessment using MRI-derived blood volume maps in glioma patients (86). Although 
not performed using DW-MRI acquired parameters, the study observed negligible effectiveness 
of a variety of whole-tumor quantitative metrics at detecting tumor response at both one and 
three week post-treatment initiation. 
An alternative image processing approach has been developed to quantify and spatially 
map the intrinsic treatment-associated heterogeneity of diffusion values within a tumor. This 
technique is referred to as functional diffusion mapping (fDM) (87). A key element of fDM is 
spatial registration of baseline and follow-up three-dimensional quantitative diffusion maps (i.e. 
ADC) into a single geometrical space. Further reading on the registration techniques and 
limitations for therapeutic response assessment is provided in Refs(85,88,89). Once registered, 
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diffusion changes are measured on a voxel-by-voxel basis from spatially aligned pretreatment, 
and post-treatment initiation ADC maps. Tumor voxels are then classified by their extent of 
change in ADC. Although fDM has been initially evaluated in glioma patients (87,90-93), this 
technique has been applied to other tumor types (29,65,76,85). Shown in Figure 5 are fDMs (also 
referred to as Parametric Response Mapping (PRMADC)) with corresponding scatter plots from 
head and neck squamous cell carcinoma (HNSCC) patients diagnosed as CR (Figure 5A) and PR 
(Figure 5B) following therapy. By analyzing the diffusion maps using fDM, heterogeneity in 
tumor response can be visualized with red regions denoting response (i.e. increase in ADC from 
baseline) versus stable and decreased ADC regions depicted as green and blue, respectively. As 
demonstrated in a variety of tumor types, large regions of increased ADC from baseline (i.e. red 
voxels) were strongly correlated with treatment response irrespective of the presence of tumor 
regions with stable or decreasing ADC values.   
 
STANDARDIZATION AND REPEATABILITY OF ADC MEASUREMENT 
 As discussed in this review the biophysical premise and technical feasibility have allowed 
quantitative DW-MRI to be a clinically viable technique. Nevertheless, for this imaging protocol 
to become routine in the management of patients and clinical trials there is a need to standardize 
DW-MRI acquisition schemes to account for intra and inter-vendor instrument variability(94). In 
an effort to bring uniformity throughout the various MRI systems, phantoms have been 
developed to confirm quantitative agreement across platforms. The ideal phantom must be stable 
throughout the imaging sequences and provide meaningful ADC measurements consistent with 
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biological systems. Due to the complexity of water diffusion in living tissue, development of a 
phantom that is both stable and mimics all tissue properties has its difficulties. Simple fluid-
based test objects are the preferred approach to phantom development using fluids that are 
thermally stable, readily available and safe when properly handled(95,96). In a study by Tofts 
and colleagues, the diffusion coefficient of 15 organic liquids were evaluated and found to stably 
provide repeatable ADC measurements within the relevant range of biological systems (0.36-
2.6x10-3mm2s)(97). In 2011, Chenevert and colleagues reported on a temperature-controlled 
phantom using water cooled to near freezing(98). This phantom consisted of liquid water 
jacketed with ice water such that the inner chamber was cooled to ~0°C. Although water 
diffusivity is highly sensitive to temperature (99), jacketing the liquid water with ice allowed a 
stable environment with temperatures maintained for up to 4 hours and a reliable, biologically 
relevant ADC value (~1x10-3mm2/s). The availability of stable and reproducible phantoms has 
allowed multi-center studies to be performed demonstrating the repeatability of quantitative DW-
MRI across platforms (100,101). 
In the absence of standard DW-MRI protocol, investigators of clinical trials are 
employing strategies for contending with intra-instrument variability. Affectionately referred to 
as the “coffee-break exam”, this approach acquires repeat DW-MRI examinations, minutes to 
hours apart, to ascertain the variability in the ADC measurement prior to therapeutic 
intervention. The motivation of this strategy is to characterize the noise associated with the ADC 
measurement for a given patient and platform in the absence of disease or treatment related 
changes in tumor physiology and anatomy. Various studies, just to name a few, have reported 
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stable quantitative DW-MRI measurements in head and neck squamous cell carcinomas(64), 
hepatocellular carcinoma(102), malignant lung lesions(103), rectal cancer (104) and primary 
beast cancer(105). Until uniformity in DW-MRI protocols between vendors, instruments and 
sites is obtained, the strategy of repeat examinations prior to therapeutic intervention will help 
elevate some of the variability in the ADC measurement within a given instrument.  
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FUTURE DIRECTIONS 
Studies presented here support the use of DW-MRI as an early surrogate biomarker for tumor 
response assessment. In a growing body of literature, changes in tumor water diffusion values 
have been reported to correlate with response to therapy despite the diverse set of tumor types, 
MRI manufacturers, magnetic field strengths used to collect the data along with the varying 
approaches used to analyse the data sets (Figure 6, Table 2). Taken together this reveals the 
overall robustness of DW-MRI for oncology treatment assessment. Clinical cancer studies on the 
efficacy of DW-MRI as a surrogate imaging biomarker of tumor treatment response have 
demonstrated that treatment-induced cell death can be detected in responding tumors as an 
increased ADC value in those regions. Due to variability in DW-MRI acquisition and analytical 
post-processing protocols, efforts have solidified in the publication of a consensus paper to 
provide for standardization across institutions (16).  In addition, temperature controlled 
phantoms have recently been developed to facilitate multi-center DW-MRI clinical trials 
(100,101). These standards are needed for data acquisition, post-image processing, timing of 
evaluation, and the method used to generate the quantifiable metric used to report treatment 
response.  While the momentum for using DW-MRI in the context of tumor response assessment 
is continuing to grow, validation of DW-MRI as a surrogate imaging biomarker of response will 
require a large, prospective, multi-institutional trial performed in a standardized fashion between 
sites. Analysis of the data could also be useful for the validation of the image post-processing 
software and for regulatory approval as a device. Having an FDA or European approved 
software package would provide additional momentum for enhancing the probability that DW-
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MRI will ultimately be incorporated into routine clinical practice for the management of cancer 
patients. Future opportunities in employing DW-MRI in the clinical management of cancer 
patients may include adaptive therapy protocols based on intra-therapy evaluation of early ADC 
changes during fractionated dosage schedules allowing for modification of interventions and for 
quantifying multi-focal disease response using wbDW-MRI (78). Finally, the recent emergence 
of anticancer immunotherapies raises an urgent need for establishing radiological metrics for 
assessing response to such experimental interventions (106-108). Further efforts investigating 
advanced imaging techniques such as DW-MRI are needed to delineate its ability to provide 
meaningful insights into treatment responsiveness in order for it to successfully impact clinical 
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Table 1 
Site  Reference  
Abdominal  (109) 
Acoustic 
Neuroma  (110) 
Bladder   (111,112) 
Bone Marrow  (113) 
Brain   (26,87,93,114-138) 
Breast  (35-38,139-152) 
Cervical  (153-160) 
Eye  (161,162) 
Leiomyoma  (163-165) 
Liver  (41,42,44,46,70,166-181) 
Lung  (182-185) 
Lymphoma  (186-188) 
Myeloma  (189,190) 
Ovarian  (191-193) 
Pancreas  (194) 
Prostate  (29,195-198) 
Rectal  (54,79,199-207) 
Sarcoma  (208-214) 
SCCHN  (65,215-220) 
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FIGURE LEGENDS 
Figure 1. A schematic of changes in water diffusivity in a tumor following an effective 
therapeutic agent. Changes in cellularity (left) occur with increased molecular water mobility 
measured as an apparent diffusion coefficient (ADC; right) as a tumor responds to treatment (top 
to bottom). As a tumor responds to therapy, an increase in extracellular space and membrane 
permeability occurs which allows for increased water mobility and detected by DW-MR as an 
increase in ADC values. (Courtesy of Ref. (18)). 
 
Figure 2. (A) ADC maps superimposed over the postcontrast DCE-MR images at 3 time points 
(pretreatment, after 1 cycle, and after all cycles of NAC) for a patient achieving pCR. The 
numbers for each panel represent the mean ADC values for each time point in the parametric 
map. (B) The difference image between precontrast and postcontrast DCE-MRI at each time 
point. (C) ADC maps superimposed over the postcontrast DCE-MR images at 3 time points 
(pretreatment, after 1 cycle, and after all cycles of NAC) for a non-pCR patient. The numbers for 
each panel represent the mean ADC values for each time point in the parametric map. (D) The 
difference image between precontrast and postcontrast DCE-MRI at each time point. (Courtesy 
of and adapted from Ref. (73)). 
 
Figure 3. Whole-Body DWI is presented as an early indicator of response to systemic therapy in 
lymphoma patients. (A) A 48-year-old male patient diagnosed with diffuse large B-cell 
lymphoma obtained at baseline shows ubiquitous involvement of lymph nodes (e.g. cervical and 
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retroperitoneal—small arrows) and in the axillary regions (large arrows) with marked restriction 
of water diffusivity. A larger pelvic node (arrowhead) is also seen left to the midline. (B) At day 
7, following institution of chemotherapy with rituximab (anti-CD20 antibodies) + CHOP 
(cyclophospamide, hydroxydaunorubicin, vincristine, prednisolone), Whole-body DW-MR 
shows evident reduction in signal intensity in the cervical and retroperitoneal node regions (small 
arrows) and axillary region (large arrows) (from ADC = 0.90/0.33/0.67/0.61 to 
ADC=1.66/0.73/1.36/1.22) with corresponding increase in ADC (not shown), but less marked 
response in the pelvic node (arrowhead) (from ADC = 0.83/0.51 to ADC = 1.12/0.67) At interim, 
the patient achieved complete remission. (Courtesy of Ref. (59)). 
 
Figure 4. Simulated comparison of whole-tumor histogram analysis (top row; the blue line is the 
pretreatment tumor data and the red line is the post treatment tumor data) versus the 
corresponding voxel-based analysis using a joint density histogram (bottom row). Histograms 
from tumors with (A) no major change, (B) significant uniform shift to higher ADC values with 
a 34% net mean change, and (C) heterogeneous ADC changes (increased and decreased ADC 
values) resulting in no net detectable histogram shift. Parametric response maps from the 
corresponding histograms above where (D) the confidence interval for detection of change was 
set to 95%, thus no significant change in red voxels (increased values) or blue voxels (decreased 
values) was detected. (E) An increase in the number of red voxels was detected at 29% of the 
total tumor voxels. (F) Both an increase and a decrease in tumor voxels of approximately 15% 
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were detected, whereas no major shift was detected using a histogram analysis of the same data 
(C). (Courtesy of Ref. (85)). 
 
Figure 5. Functional Diffusion Mapping (fDM) applied to clinical data acquired from HNSCC 
patients diagnosed as (A) pCR (pathological complete response) and (B) PR (partial response). 
Results from the fDM analysis are presented as color-coded maps superimposed on contrast-
enhanced T1-weighted images and scatter plots with axes pretreatment ADC (x-axis) and post-
treatment ADC (y-axis). Color-coding is as followed: red indicates increased ADC values, blue 
indicates decreased ADC values and green indicates unchanged ADC values. (Courtesy of Ref. 
(65)). 
 
Figure 6. Number of annual publications on the application of DW-MRI for therapeutic response 
assessment. Yearly evaluation showed a growing increase in the number of studies 
demonstrating the efficacy of DW-MRI for cancer response to treatment. Search was performed 
on Pubmed using the following criteria [((diffusion OR ADC OR "apparent diffusion 
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DW-MRI is sensitive to cellular changes and has 
been extensively evaluated as a quantitative and 
early imaging biomarker of therapeutic response. 
DW-MR can be applied to many different solid 
tumors to detect changes in cellularity as 
measured by an early increase in the apparent 
diffusion coefficient (ADC) of water molecules 
within the lesion. An overview of DW-MRI 
acquisition protocols, quantitative image analysis 
approaches and an overview of applications 
implementing DW-MRI for early prediction of 
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